Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David C Smith

Showing results (131-140 of 168) with videos related to

Pageof 17
Sort By:
Chemistry (Weinheim an Der Bergstrasse, Germany)|November 27, 2015
A Versatile Precursor System for Supercritical Fluid Electrodeposition of Main-Group MaterialsPhilip N Bartlett, Jennifer Burt, David A Cook, et al.
Cancer|January 10, 2019
A phase 1 trial of SGN-CD70A in patients with CD70-positive, metastatic renal cell carcinomaSumanta K Pal, Andres Forero-Torres, John A Thompson, et al.
Neoplasia (New York, N.Y.)|January 26, 2016
Mechanistic Support for Combined MET and AR Blockade in Castration-Resistant Prostate CancerYuanyuan Qiao, Felix Y Feng, Yugang Wang, et al.
Investigational New Drugs|March 18, 2015
Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignanciesDavid C Smith, Thea Kalebic, Jeffrey R Infante, et al.
International Journal of Molecular Sciences|January 11, 2022
Multigene Profiling of Circulating Tumor Cells (CTCs) for Prognostic Assessment in Treatment-Naïve Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)Zachery R Reichert, Tadas Kasputis, Srinivas Nallandhighal, et al.
Cancer Management and Research|December 20, 2019
First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced MalignancyPamela Munster, Monica Mita, Amit Mahipal, et al.
Cancer|November 20, 2013
Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinomaPetros D Grivas, Stephanie Daignault, Scott T Tagawa, et al.
Investigational New Drugs|May 3, 2014
A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patientsAnna Spreafico, Kim N Chi, Srikala S Sridhar, et al.
Molecular Cancer Research : MCR|February 18, 2018
Multigene Profiling of CTCs in mCRPC Identifies a Clinically Relevant Prognostic SignatureUdit Singhal, Yugang Wang, James Henderson, et al.
Investigational New Drugs|March 26, 2010
Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortiumDeborah A Bradley, Stephanie Daignault, Charles J Ryan, et al.
Pageof 17

Showing results (131-140 of 168) with videos related to

Sort By:
Pageof 17
Chemistry (Weinheim an Der Bergstrasse, Germany)|November 27, 2015
A Versatile Precursor System for Supercritical Fluid Electrodeposition of Main-Group MaterialsPhilip N Bartlett, Jennifer Burt, David A Cook, et al.
Cancer|January 10, 2019
A phase 1 trial of SGN-CD70A in patients with CD70-positive, metastatic renal cell carcinomaSumanta K Pal, Andres Forero-Torres, John A Thompson, et al.
Neoplasia (New York, N.Y.)|January 26, 2016
Mechanistic Support for Combined MET and AR Blockade in Castration-Resistant Prostate CancerYuanyuan Qiao, Felix Y Feng, Yugang Wang, et al.
Investigational New Drugs|March 18, 2015
Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignanciesDavid C Smith, Thea Kalebic, Jeffrey R Infante, et al.
International Journal of Molecular Sciences|January 11, 2022
Multigene Profiling of Circulating Tumor Cells (CTCs) for Prognostic Assessment in Treatment-Naïve Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)Zachery R Reichert, Tadas Kasputis, Srinivas Nallandhighal, et al.
Cancer Management and Research|December 20, 2019
First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced MalignancyPamela Munster, Monica Mita, Amit Mahipal, et al.
Cancer|November 20, 2013
Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinomaPetros D Grivas, Stephanie Daignault, Scott T Tagawa, et al.
Investigational New Drugs|May 3, 2014
A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patientsAnna Spreafico, Kim N Chi, Srikala S Sridhar, et al.
Molecular Cancer Research : MCR|February 18, 2018
Multigene Profiling of CTCs in mCRPC Identifies a Clinically Relevant Prognostic SignatureUdit Singhal, Yugang Wang, James Henderson, et al.
Investigational New Drugs|March 26, 2010
Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortiumDeborah A Bradley, Stephanie Daignault, Charles J Ryan, et al.
Pageof 17